PIQ Stock Overview
Proteomics International Laboratories Limited operates as a medical technology company with a focus on the area of proteomics.
| Snowflake Score | |
|---|---|
| Valuation | 0/6 |
| Future Growth | 2/6 |
| Past Performance | 0/6 |
| Financial Health | 6/6 |
| Dividends | 0/6 |
Proteomics International Laboratories Limited Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | AU$1.10 |
| 52 Week High | AU$1.40 |
| 52 Week Low | AU$0.70 |
| Beta | 0.61 |
| 1 Month Change | 1.39% |
| 3 Month Change | 19.02% |
| 1 Year Change | 23.73% |
| 3 Year Change | -3.10% |
| 5 Year Change | 291.07% |
| Change since IPO | 386.67% |
Recent News & Updates
Most Shareholders Will Probably Find That The CEO Compensation For Proteomics International Laboratories Limited (ASX:PIQ) Is Reasonable
Nov 16
Calculating The Fair Value Of Proteomics International Laboratories Limited (ASX:PIQ)
Sep 29Recent updates
Most Shareholders Will Probably Find That The CEO Compensation For Proteomics International Laboratories Limited (ASX:PIQ) Is Reasonable
Nov 16Calculating The Fair Value Of Proteomics International Laboratories Limited (ASX:PIQ)
Sep 29We're Hopeful That Proteomics International Laboratories (ASX:PIQ) Will Use Its Cash Wisely
May 10Here's Why We Think Proteomics International Laboratories Limited's (ASX:PIQ) CEO Compensation Looks Fair for the time being
Nov 17Is Proteomics International Laboratories (ASX:PIQ) In A Good Position To Invest In Growth?
Aug 09We Think Proteomics International Laboratories (ASX:PIQ) Can Afford To Drive Business Growth
Oct 20We're Not Worried About Proteomics International Laboratories' (ASX:PIQ) Cash Burn
May 31Shareholder Returns
| PIQ | AU Life Sciences | AU Market | |
|---|---|---|---|
| 7D | 0.5% | -4.0% | 0.4% |
| 1Y | 23.7% | -17.1% | 6.0% |
Return vs Industry: PIQ exceeded the Australian Life Sciences industry which returned -17.1% over the past year.
Return vs Market: PIQ exceeded the Australian Market which returned 6% over the past year.
Price Volatility
| PIQ volatility | |
|---|---|
| PIQ Average Weekly Movement | 11.0% |
| Life Sciences Industry Average Movement | 10.5% |
| Market Average Movement | 8.9% |
| 10% most volatile stocks in AU Market | 17.6% |
| 10% least volatile stocks in AU Market | 3.5% |
Stable Share Price: PIQ's share price has been volatile over the past 3 months.
Volatility Over Time: PIQ's weekly volatility (11%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2001 | n/a | Richard Lipscombe | www.proteomics.com.au |
Proteomics International Laboratories Limited operates as a medical technology company with a focus on the area of proteomics. It provides PromarkerD, a predictive test for diabetic kidney disease; and develops diagnostic tests for endometriosis and giardia. The company also offers analytical services, including specialist contract research.
Proteomics International Laboratories Limited Fundamentals Summary
| PIQ fundamental statistics | |
|---|---|
| Market cap | AU$142.67m |
| Earnings (TTM) | -AU$5.90m |
| Revenue (TTM) | AU$3.03m |
47.3x
P/S Ratio-24.3x
P/E RatioIs PIQ overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| PIQ income statement (TTM) | |
|---|---|
| Revenue | AU$3.03m |
| Cost of Revenue | AU$2.11m |
| Gross Profit | AU$920.25k |
| Other Expenses | AU$6.82m |
| Earnings | -AU$5.90m |
Last Reported Earnings
Dec 31, 2023
Next Earnings Date
n/a
| Earnings per share (EPS) | -0.045 |
| Gross Margin | 30.35% |
| Net Profit Margin | -194.61% |
| Debt/Equity Ratio | 0% |
How did PIQ perform over the long term?
See historical performance and comparison